Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Li BT, et al. Among authors: hyman dm. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989854 Free PMC article. Clinical Trial.
Tumor Genetic Screening Programs: A Call to Action.
Hyman DM, Solit DB. Hyman DM, et al. J Clin Oncol. 2015 Sep 1;33(25):2725-6. doi: 10.1200/JCO.2015.61.9296. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195721 No abstract available.
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Benayed R, Offin M, Mullaney K, Sukhadia P, Rios K, Desmeules P, Ptashkin R, Won H, Chang J, Halpenny D, Schram AM, Rudin CM, Hyman DM, Arcila ME, Berger MF, Zehir A, Kris MG, Drilon A, Ladanyi M. Benayed R, et al. Among authors: hyman dm. Clin Cancer Res. 2019 Aug 1;25(15):4712-4722. doi: 10.1158/1078-0432.CCR-19-0225. Epub 2019 Apr 26. Clin Cancer Res. 2019. PMID: 31028088 Free PMC article.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: hyman dm. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G. Grisham RN, et al. Among authors: hyman dm. J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31. J Clin Oncol. 2015. PMID: 26324360 Free PMC article.
Reply to M.P. Decatris et al.
Hyman DM, Solit DB, Iasonos A. Hyman DM, et al. J Clin Oncol. 2016 Mar 10;34(8):887. doi: 10.1200/JCO.2015.65.2487. Epub 2016 Jan 11. J Clin Oncol. 2016. PMID: 26755514 No abstract available.
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.
Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A. Cunanan KM, et al. Among authors: hyman dm. J Clin Oncol. 2017 Jan 20;35(3):271-273. doi: 10.1200/JCO.2016.69.9751. Epub 2016 Nov 28. J Clin Oncol. 2017. PMID: 27893325 Free PMC article. Review. No abstract available.
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M. Cocco E, et al. Among authors: hyman dm. Sci Signal. 2018 Oct 9;11(551):eaat9773. doi: 10.1126/scisignal.aat9773. Sci Signal. 2018. PMID: 30301790 Free PMC article.
204 results